Eli Lilly (LLY) EVP Van Naarden converts RSUs and withholds shares
Rhea-AI Filing Summary
Eli Lilly executive Jacob Van Naarden, EVP and President of LLY Oncology & Head of Corporate Business Development, reported equity movements in Eli Lilly common stock. On February 1, 2026, 4,108 restricted stock units were converted into the same number of common shares at an exercise price of $0, bringing his directly held common stock to 24,669.985 shares.
On the same date, 1,909.375 shares of common stock were withheld at a price of $1,037.15 per share, typically for tax obligations, leaving him with 22,760.61 shares of Eli Lilly common stock held directly. Separately, 4,342 shares are held indirectly through the Van Naarden Family Trust and 4,302 shares are held indirectly by his spouse. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 4,108 | $0.00 | -- |
| Exercise | Common Stock | 4,108 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,909.375 | $1,037.15 | $1.98M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.
